This Plain Language Summary of Publication article (PLSP) from Immunotherapy explains the ADACCESS study, which compared two adalimumab medicines in people with plaque psoriasis: reference adalimumab (Humira®) and biosimilar GP2017 (Hyrimoz®). Some participants used one medicine throughout the study, while others switched between the two medicines to evaluate their effectiveness and safety.

Visit the site using this link to read the article.

This PLSP is based on two articles called ‘Comparing anti-drug antibody signal-to-noise ratios to assess immunogenicity and interchangeability in adalimumab biosimilar studies’ and was published in Expert Opinion on Biological Therapy.

‘Phase III randomized study of the proposed adalimumab biosimilar GP2017 in psoriasis: impact of multiple switches’ and was published in the British Journal of Dermatology.

Visit Taylor & Francis Online using the link to read the original article.

Visit Oxford Academic using the link to read the original article.